Literature DB >> 16520857

Acute coronary syndrome induced by oral capecitabine.

Daniela Cardinale1, Alessandro Colombo, Nicola Colombo.   

Abstract

A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation. After spontaneous pain relief, the electrocardiogram showed ischemic evolution in the anterior precordial leads. Coronary and ventricular angiography, performed 24 h later, showed normal coronary arteries and normal left ventricular function. After therapy with capecitabine was discontinued, the patient did not experience further episodes of chest pain. After a nine-month follow-up, she remains alive, with a good performance status and without clinical evidence of persistent ischemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520857      PMCID: PMC2528921          DOI: 10.1016/s0828-282x(06)70905-9

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  21 in total

1.  Coronary spasm induced by capecitabine.

Authors:  B Schnetzler; N Popova; C Collao Lamb; A P Sappino
Journal:  Ann Oncol       Date:  2001-05       Impact factor: 32.976

Review 2.  5-Fluorouracil cardiotoxicity: a critical review.

Authors:  W J Gradishar; E E Vokes
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

3.  The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture.

Authors:  M Cwikiel; J Eskilsson; M Albertsson; L Stavenow
Journal:  Ann Oncol       Date:  1996-09       Impact factor: 32.976

Review 4.  Capecitabine: a review.

Authors:  Christine M Walko; Celeste Lindley
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

Review 5.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 6.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

7.  In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.

Authors:  M Mosseri; H J Fingert; L Varticovski; S Chokshi; J M Isner
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

8.  Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

Authors:  M de Forni; M C Malet-Martino; P Jaillais; R E Shubinski; J M Bachaud; L Lemaire; P Canal; C Chevreau; D Carrié; P Soulié
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

Review 9.  Oral chemotherapy: rationale and future directions.

Authors:  M D DeMario; M J Ratain
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

Review 10.  Acute cardiotoxicity during capecitabine treatment: a case report.

Authors:  A Bertolini; M Flumanò; O Fusco; A Muffatti; A Scarinci; G Pontiggia; M Scopelliti
Journal:  Tumori       Date:  2001 May-Jun
View more
  16 in total

Review 1.  Ischemic Heart Disease: Special Considerations in Cardio-Oncology.

Authors:  Dana Elena Giza; Fernando Boccalandro; Juan Lopez-Mattei; Gloria Iliescu; Kaveh Karimzad; Peter Kim; Cezar Iliescu
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-05

Review 2.  Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.

Authors:  Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

Review 3.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

Authors:  Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

Review 4.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

5.  Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.

Authors:  Omar Dzaye; Suzy Cleator; Petros Nihoyannopoulos
Journal:  BMJ Case Rep       Date:  2014-09-22

Review 6.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

Review 7.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 8.  Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge.

Authors:  Bibhu D Mohanty; Sudipta Mohanty; Yasin Hussain; Chandrasekhar Padmaraju; Sameer Aggarwal; Rebekah Gospin; Anthony F Yu
Journal:  Future Cardiol       Date:  2017-06-01

9.  Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm.

Authors:  Suparna C Clasen; Bonnie Ky; Rupal O'Quinn; Bruce Giantonio; Ursina Teitelbaum; Joseph R Carver
Journal:  J Gastrointest Oncol       Date:  2017-12

10.  Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.

Authors:  Sanjay Goel; Kavita Desai; Sirisha Karri; Radharani Gollamudi; Imran Chaudhary; Anca Bulgaru; Andreas Kaubisch; Gary Goldberg; Mark Einstein; Fernando Camacho; Sharyn Baker; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-12-30       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.